Effects of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) on the Interleukin-6 Expression in the Prostate Cancer Cell Line PC-3.
10.4111/kju.2006.47.7.786
- Author:
Goon Hyun KANG
1
;
Soon Chul MYUNG
;
Tae Hyung KIM
;
Seung Young OH
;
Eun Ha WON
;
Sang Chul KIM
;
Wha Su KIM
;
Young Sun KIM
Author Information
1. Department of Urology, Chung-Ang University Hospital, Seoul, Korea. kthlmk@hanafos.com
- Publication Type:Original Article
- Keywords:
Prostate cancer;
Interleukin-6;
Granulocyte-macrophage colony-stimulating factor
- MeSH:
Cell Line*;
Enzyme-Linked Immunosorbent Assay;
Granulocyte-Macrophage Colony-Stimulating Factor;
Granulocytes*;
Humans;
Interleukin-6*;
Macrophage Colony-Stimulating Factor*;
Macrophages*;
Polymerase Chain Reaction;
Prostate*;
Prostatic Neoplasms*;
Reverse Transcription;
RNA, Messenger
- From:Korean Journal of Urology
2006;47(7):786-790
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Interleukin-6 (IL-6) can stimulate a variety of tumors including prostatic carcinoma. Research has recently shown that IL-6 may act to stimulate the progression of prostatic cancer. IL-6 is elevated in the sera of patients with metastatic prostatic cancer and it has been shown to be a candidate marker of disease activity. To date, little work has been performed to characterize the nature of granulocyte macrophage colony-stimulating factor (GM-CSF) and the expression of IL-6. The aim of this study is to evaluate the effects of GM-CSF on the expression of IL-6 in PC-3 cells. MATERIALS AND METHODS: The bone-derived PC-3 cell line was used in this study. Reverse transcription polymerase chain reaction (RT-PCR) was performed to detect the GM-CSF and also the IL-6 mRNA expression. The IL-6 protein was measured by enzyme-linked immunosorbent assay (ELISA) after treatments with the hGM-CSF. RESULTS: hGM-CSF was expressed in the PC-3 cell line. Our data indicated that the IL-6 mRNA expression was not increased at 4, 8 and 12 hours by the hGM-CSF in comparison to the control group, but it was slightly increased at 24 and 48 hours. The expression of IL-6 protein was increased at 4, 8, 12, 24 and 48 hours after hGM-CSF treatment, in comparison with the control group. CONCLUSIONS: The IL-6 mRNA expression was slightly increased by hGM-CSF at 24 and 48 hours in comparison to the control group. Yet the IL-6 protein expression increased before the IL-6 mRNA expression. Therefore, hGM-CSF may modulate the post-transcription pathway of the IL-6 expression in prostate carcinoma cells. Our data suggest that GM-CSF may have a possible IL-6 mediated pathophysiologic role in prostate cancer.
